Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience

BACKGROUND: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed dose of 1800 mg. However, the subcutaneous formulation has only recently been approved in Europe, and...

Descripción completa

Detalles Bibliográficos
Autores principales: De Novellis, Danilo, Fontana, Raffaele, Palmieri, Salvatore, Della Pepa, Roberta, Di Perna, Maria, Cetani, Giusy, Esposito, Daniela, Amendola, Angela, Delle Cave, Giuseppe, Serio, Bianca, Morini, Denise, Rizzo, Michela, Mettivier, Laura, Trastulli, Fabio, Rocco, Stefano, Pagano, Anastasia, Barbato, Serafina, Leone, Aldo, La Magna, Martina, Bianco, Rosario, Rascato, Gabriella, Carobene, Angela, Cuffa, Bianca, Iannalfo, Marialuigia, Giudice, Valentina, Svanera, Gino, Annunziata, Mario, Pizzuti, Michele, Frigeri, Ferdinando, Califano, Catello, Ferrara, Felicetto, Pane, Fabrizio, Selleri, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663178/
https://www.ncbi.nlm.nih.gov/pubmed/37747623
http://dx.doi.org/10.1007/s11523-023-01001-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663178/
https://www.ncbi.nlm.nih.gov/pubmed/37747623
http://dx.doi.org/10.1007/s11523-023-01001-4

Ejemplares similares